Skip to content

ORGO · NASDAQ

Organogenesis Holdings (ORGO) Stock Price & Fundamentals

$300.07−0.04%−$0.13End-of-day price as of Oct 9, 2026

Organogenesis Holdings (ORGO) closed at $300.07 on Oct 9, 2026, down 0.04% from the previous close of $300.20.

Share price, past year

1Y +4.10%

52-week range $246.48 – $323.25. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$300.07
Sep 30, 2026$302.05
Aug 31, 2026$315.93
Jul 31, 2026$309.13
Jun 30, 2026$276.45
May 29, 2026$268.36
Apr 30, 2026$261.49
Mar 31, 2026$247.78
Feb 27, 2026$260.04
Jan 30, 2026$279.25
Dec 31, 2025$297.91
Nov 28, 2025$287.86
Oct 31, 2025$286.90

Key statistics

Market cap
$38.61B
P/E (TTM)
—
EPS (TTM)
−$0.79
Revenue (TTM)
$457.45M
Net income (TTM)
−$84.16M
Shares outstanding
128.7M
Dividend yield
—
52-week range
$246.48 – $323.25

Organogenesis Holdings's market cap is $38.61B, based on a share price of $300.07 and 128.7M shares outstanding as of Jun 30, 2026.

Financials

Organogenesis Holdings reported revenue of $564.17M for fiscal 2025, up 17.04% from fiscal 2024.

Organogenesis Holdings earned net income of $37.03M in fiscal 2025, a net margin of 6.6%.

Fiscal 2025 revenue was the highest in the 10 years shown.

Annual revenue

FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Annual revenue by fiscal year; the table below lists the values.
Organogenesis Holdings annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2025ended Dec 31, 2025$564.17M+17.0%$37.03M6.6%$0.15−$24.46M
FY2024ended Dec 31, 2024$482.04M+11.3%$861.00K0.2%−$0.01$4.18M
FY2023ended Dec 31, 2023$433.14M−3.9%$4.95M1.1%$0.04$6.55M
FY2022ended Dec 31, 2022$450.89M−3.5%$15.53M3.4%$0.12−$9.04M
FY2021ended Dec 31, 2021$467.36M+38.2%$94.20M20.2%$0.70$30.76M
FY2020ended Dec 31, 2020$338.30M+29.6%$17.23M5.1%$0.15−$12.21M
FY2019ended Dec 31, 2019$260.98M+34.9%−$38.71M−14.8%−$0.42−$39.51M
FY2018ended Dec 31, 2018$193.45M−2.6%−$64.83M−33.5%−$0.94−$62.49M
FY2017ended Dec 31, 2017$198.51M+43.1%−$8.39M−4.2%−$0.14−$5.92M
FY2016ended Dec 31, 2016$138.73M—−$16.99M−12.2%−$0.27−$6.23M
Organogenesis Holdings quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q2 FY2026ended Jun 30, 2026$43.76M−$96.27M−$0.77
Q1 FY2026ended Mar 31, 2026$37.23M−$53.16M−$0.44
Q4 FY2025ended Dec 31, 2025$225.61M$43.70M$0.31
Q3 FY2025ended Sep 30, 2025$150.86M$21.57M$0.11
Q2 FY2025ended Jun 30, 2025$101.01M−$9.39M−$0.10
Q1 FY2025ended Mar 31, 2025$86.69M−$18.84M−$0.17
Q4 FY2024ended Dec 31, 2024$126.66M$7.67M$0.05
Q3 FY2024ended Sep 30, 2024$115.18M$12.33M$0.09

Company profile

Name
Organogenesis Holdings Inc.
Ticker
ORGO
Exchange
NASDAQ
Industry (SEC SIC)
Pharmaceutical Preparations
Headquarters
85 Dan Road, Canton, MA 02021
Incorporated in
DE
Fiscal year ends
December
SEC CIK
0001661181

Recent SEC filings

Frequently asked questions

What is Organogenesis Holdings's stock price?

Organogenesis Holdings (ORGO) closed at $300.07 on Oct 9, 2026, down 0.04% from the previous close of $300.20.

What is Organogenesis Holdings's market cap?

Organogenesis Holdings's market cap is $38.61B, based on a share price of $300.07 and 128.7M shares outstanding as of Jun 30, 2026.

How much revenue does Organogenesis Holdings make?

Organogenesis Holdings reported revenue of $564.17M for fiscal 2025, up 17.04% from fiscal 2024.

Does Organogenesis Holdings pay a dividend?

Organogenesis Holdings's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from Organogenesis Holdings Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures